Infective endocarditis: Difference between revisions
From IDWiki
Content deleted Content added
cleaned up, and added management table with staphylococci |
|||
| Line 1: | Line 1: | ||
== Background == |
|||
* Infection of heart valves |
* Infection of heart valves, either prosthetic or native |
||
| ⚫ | |||
| ⚫ | |||
* '''Bacteria''' |
* '''Bacteria''' |
||
** [[Staphylococcus aureus]] (most common) |
** [[Staphylococcus aureus]] (most common) |
||
** [[Viridans group streptococci]] |
** [[Viridans group streptococci]] |
||
** [[Coagulase-negative |
** [[Coagulase-negative staphylococci]] |
||
** Other streptococci |
** Other streptococci |
||
** [[Enterococci]] |
** [[Enterococci]] |
||
| Line 15: | Line 15: | ||
** ''[[Candidal endocarditis|Candida]]'' |
** ''[[Candidal endocarditis|Candida]]'' |
||
== Presentation == |
== Clinical Presentation == |
||
| ⚫ | |||
* Specific organisms may be associated with specific risk factors |
|||
| ⚫ | |||
* |
** Injection drug use: [[Viridans group streptococci]] and ''[[Pseudomonas aeruginosa]]'' |
||
* Colon cancer: ''Streptococcus bovis'' and ''Clostridium septicum'' |
** Colon cancer: ''[Streptococcus bovis]]'' and ''[[Clostridium septicum]]'' |
||
== |
== Management == |
||
* Varies by causative organism and prosthetic vs. native valve |
|||
{| class="wikitable" |
|||
* MSSA native valve endocarditis |
|||
! Organism |
|||
** [[Cloxacillin]] or [[cefazolin]] |
|||
! Indication |
|||
** OR [[Vancomycin]]/[[Daptomycin]] |
|||
! Antibiotic |
|||
* MSSA prosthetic valve endocarditis |
|||
! Dose |
|||
| ⚫ | |||
! Duration |
|||
** OR [[Vancomycin]]/[[Daptomycin]], other things |
|||
! Notes |
|||
* 6 weeks |
|||
|- |
|||
| Oxacillin-susceptible [[Staphylococcus]] |
|||
| NVE |
|||
| [[oxacillin]] || 12 g/day IV in 4-6 divided doses || 6 weeks |
|||
| can treat for 2 weeks in uncomplicated right-sided NVE |
|||
|- |
|||
| Oxacillin-susceptible [[Staphylococcus]] |
|||
| NVE |
|||
| [[cefazolin]] || 6 g/day IV in 3 divided doses || 6 weeks |
|||
| in patients with non-anaphylactoid penicillin allergy |
|||
|- |
|||
| Oxacillin-resistant [[Staphylococcus]] |
|||
| NVE |
|||
| [[vancomycin]] || 30 mg/kg/day IV in 2 divided doses || 6 weeks |
|||
| target trough 10-20 μg/mL |
|||
|- |
|||
| Oxacillin-resistant [[Staphylococcus]] |
|||
| NVE |
|||
| [[daptomycin]] || ≥8 mg/kg/dose || 6 weeks |
|||
| |
|||
|- |
|||
| Oxacillin-susceptible [[Staphylococcus]] |
|||
| PVE |
|||
| ⚫ | |||
| 12 g/day in 6 divided doses<br/>900 mg/day IV or PO in 3 divided doses<br/>3 mg/kg/day IV or IM in 2-3 divided doses |
|||
| ≥6 weeks<br/>≥6 weeks<br/>2 weeks |
|||
| use cefazolin or vancomycin if allergy |
|||
|- |
|||
| Oxacillin-resistant [[Staphylococcus]] |
|||
| PVE |
|||
| [[vancomycin]], plus<br/>[[rifampin]], plus<br/>[[gentamicin]] |
|||
| 30 mg/kg/day in 2 divided doses<br/>900 mg/day IV or PO in 3 divided doses<br/>3 mg/kg/day IV or IM in 2-3 divided doses |
|||
| ≥6 weeks<br/>≥6 weeks<br/>2 weeks |
|||
| target trough of 10-20 μg/mL |
|||
|} |
|||
[[Category:Cardiac infections]] |
[[Category:Cardiac infections]] |
||
Revision as of 01:12, 10 March 2020
Background
- Infection of heart valves, either prosthetic or native
Organisms
- Bacteria
- Staphylococcus aureus (most common)
- Viridans group streptococci
- Coagulase-negative staphylococci
- Other streptococci
- Enterococci
- HACEK group
- Coxiella
- Brucella
- Fungi
Clinical Presentation
- Refer to Modified Duke criteria
- Specific organisms may be associated with specific risk factors
- Injection drug use: Viridans group streptococci and Pseudomonas aeruginosa
- Colon cancer: [Streptococcus bovis]] and Clostridium septicum
Management
- Varies by causative organism and prosthetic vs. native valve
| Organism | Indication | Antibiotic | Dose | Duration | Notes |
|---|---|---|---|---|---|
| Oxacillin-susceptible Staphylococcus | NVE | oxacillin | 12 g/day IV in 4-6 divided doses | 6 weeks | can treat for 2 weeks in uncomplicated right-sided NVE |
| Oxacillin-susceptible Staphylococcus | NVE | cefazolin | 6 g/day IV in 3 divided doses | 6 weeks | in patients with non-anaphylactoid penicillin allergy |
| Oxacillin-resistant Staphylococcus | NVE | vancomycin | 30 mg/kg/day IV in 2 divided doses | 6 weeks | target trough 10-20 μg/mL |
| Oxacillin-resistant Staphylococcus | NVE | daptomycin | ≥8 mg/kg/dose | 6 weeks | |
| Oxacillin-susceptible Staphylococcus | PVE | oxacillin, plus rifampin, plus gentamicin |
12 g/day in 6 divided doses 900 mg/day IV or PO in 3 divided doses 3 mg/kg/day IV or IM in 2-3 divided doses |
≥6 weeks ≥6 weeks 2 weeks |
use cefazolin or vancomycin if allergy |
| Oxacillin-resistant Staphylococcus | PVE | vancomycin, plus rifampin, plus gentamicin |
30 mg/kg/day in 2 divided doses 900 mg/day IV or PO in 3 divided doses 3 mg/kg/day IV or IM in 2-3 divided doses |
≥6 weeks ≥6 weeks 2 weeks |
target trough of 10-20 μg/mL |